ERBB2 and breast carcinoma: Hence, our findings suggest that Al18F-NOTA-HER2-BCH PET/CT imaging offers a viable alternative to conventional nonspecific radiotracers for the noninvasive assessment of HER2 expression in breast cancer lesions.